77.4 F
San Diego
Sunday, Sep 25, 2022
-Advertisement-

Conatus Pharmaceuticals Receives $7.5M in Follow-On Investment

Conatus Pharmaceuticals Inc., a San Diego biotech firm researching treatment of liver disease and cancer, said April 12 it obtained $7.5 million in a follow-on investment by MPM Capital of south San Francisco.

The latest round brings the total invested to $32.5 million, Conatus said.

The company said it plans to use the funds to advance the clinical development of CTS-1027, a clinical stage drug candidate it licensed from F. Hoffmann-LaRoche Ltd and the subject of multiple stage 2 trials in hepatitis C patients.

The additional funding permits Conatus to move ahead with trials that were started in January as well as evaluation of compounds that were acquired last year with Idun Pharmaceuticals, the company said.

- Advertisement -

-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-